Hadar Duskin-Bitan

Hadar Duskin-Bitan

Auto-generated profile, based on publicly available information

Hadar Duskin-Bitan

Gray School of Medicine Tel Aviv University Tel Aviv Israel

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
AGAlexander Gorshtein
Alexander Gorshtein
ATAdi Turjeman
Adi Turjeman
HDHadar Duskin-Bitan
Hadar Duskin-Bitan
LLLeonard Leibovici
Leonard Leibovici
EREyal Robenshtok
Eyal Robenshtok
Objective: Multiple cases and case series reported Graves’ disease (GD) following coronavirus disease 2019 (COVID-19) vaccination. We aimed to determine whether COVID-19 vaccination was associated with the incidence of GD.Methods: We analyzed data from Clalit Health Services, the largest healthcare organization in Israel, which insures 4.7 million patients. A population-based, matched, case-control study was performed. Cases were defined as adult patients diagnosed with GD between December 2020 and November 2022. Each case was matched with controls in a 1:2 ratio. Each control was assigned an index date, which was identical to that of their matched case, defined as the date of GD diagnosis. Time between vaccination date and the diagnosis of GD or index date was assessed.Results: A total of 726 patients with GD were matched with 1452 controls. The study patients and controls have received similar proportions of the COVID-19 vaccine [at least 1 dose: 80% (581/726) vs 77.8% (1129/1452), P = .22, respectively]. In a univariate analysis, at least 1 dose of the COVID-19 vaccine was not associated with the incidence of GD [odds ratio 95% confidence interval: 1.15 (.92-1.43)]. The mean time between first COVID-19 vaccination and the diagnosis of GD for cases or index date for controls was not significantly different [275.69 days (SD 144.37) for cases compared to 275.45 days (SD 145.76) for controls].Conclusion: Our study found no association between COVID-19 vaccination and the incidence of GD.

18 August 2024 in Clinical Endocrinology
Verified
Journal Article
Open access
YRYaron Rudman
Yaron Rudman
HDHadar Duskin‐Bitan
Hadar Duskin‐Bitan
HMHiba Masri-Iraqi
Hiba Masri-Iraqi
Amit AkirovAmit Akirov
Amit Akirov
ISIlan Shimon
Ilan Shimon
Objective: The management of visual field damage in patients with macroprolactinomas is a major therapeutic challenge. We aimed to study the visual morbidity associated with macroprolactinoma and its outcomes following medical and surgical treatment. We aimed to identify predictors of visual recovery. Methods: We retrospectively reviewed patient's data including clinical presentation, serial pituitary magnetic resonance imaging, laboratory tests, visual symptoms and neuro‐ophthalmologic examination, visual field tests and optical coherence tomography tests. The main outcome was complete visual field recovery. Descriptive analyses were conducted. Predictors of visual recovery were investigated. Patients: The study cohort included 150 patients with macroprolactinoma [median follow‐up, 6.0 years (interquartile range (IQR) 2.9–10.6)]. Results: At diagnosis, visual field defects were evident in 40 patients (26.7%). At the end of follow‐up, 24 out of 39 available visual field tests (61.5%) exhibited complete recovery. Patients that achieved complete visual recovery had smaller macroadenomas at diagnosis [30.5 mm (15.0–80.0) vs. 42.0 mm (30.0–85.0), p < .01], lower baseline serum prolactin levels [1414 mcg/L (489–3586) vs. 4119 mcg/L (2715–6315), p < .01], lower rates of central hypogonadism (78.3% vs. 93.3%, p = .05) and central hypothyroidism (20.8% vs. 53.3%, p = .04), lower rates of compressive optic neuropathy (35.3% vs. 87.5%, p = .02) and a better visual acuity (better than 6/8 in both eyes, 93.7% vs. 28.6%, p < .01). Conclusions: In our cohort of 150 patients with macroprolactinoma, 40 patients (26.7%) presented with visual field defects, of which 61.5% achieved complete visual recovery with treatment. Patients that achieved complete visual recovery presented with smaller macroadenomas, lower serum prolactin levels, lower rates of central hypogonadism and central hypothyroidism, lower rates of compressive optic neuropathy and better visual acuity.

9 April 2025 in Endocrine
Verified
Journal Article
Open access
PDF file
YRYaron Rudman
Yaron Rudman
NSNeta Simon
Neta Simon
RSRona Shimon
Rona Shimon
GDGenady Drozdinsky
Genady Drozdinsky
EMEfrat Markus
Efrat Markus
ISIlan Shimon
Ilan Shimon
Purpose: Due to the low incidence of male microprolactinoma, there is a paucity of data in the literature regarding its management. Our aim was to investigate the long-term outcomes of cabergoline treatment in men with microprolactinoma. Methods: In this single-center retrospective cohort study, we reviewed patient’s records at prolactinoma diagnosis, following cabergoline discontinuation (if occurred), and at the last clinic visit. We collected all available clinical data, laboratory tests, and pituitary magnetic resonance imaging. We report response rates, gonadal axis recovery, and outcomes following cabergoline discontinuation. Results: The study cohort included 47 men with microprolactinoma [age at diagnosis 45.6 ± 17.6 years; median prolactin 70.0 ng/ml (IQR 51.0–103.4); low testosterone, 34 men (72.3%); adenoma diameter 5.6 ± 2.0 mm; median follow-up 7.1 years (IQR 3.5–10.4)]. Forty-two patients (89.4%) achieved normal prolactin levels within a median treatment time of 4.0 months (IQR 3.0–5.5) and had normal testosterone at last clinic visit. Five men (10.6%) did not achieve prolactin normalization, of whom 3 men remained hypogonadal. Mild side effects occurred in 4.3% of patients and disappeared with dose reduction. Thirteen men that achieved normal prolactin attempted drug discontinuation, but only 5 remained with normoprolactinemia. Men who maintained normal prolactin levels were treated longer with cabergoline [median treatment of 10 years (IQR 4.6–10.3) vs 2.0 years (IQR 1.5–3.2); p < 0.01]. Conclusions: Ninety percent of men harboring microprolactinoma achieved normoprolactinemia and subsequent testosterone normalization with cabergoline treatment. Men that discontinued cabergoline after prolonged prolactin suppression (>5 years) achieved sustained remission. These findings assist informed decision-making, between medical and surgical treatment.

10 March 2025 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
HDHadar Duskin-Bitan
Hadar Duskin-Bitan
APAlon Perez
Alon Perez
DNDoron Netzer
Doron Netzer
ACArnon D. Cohen
Arnon D. Cohen
DCDoron Comaneshter
Doron Comaneshter
ISIlan Shimon
Ilan Shimon
The association between acromegaly and cancer had been assessed mainly in population studies with inconsistent results. The objective of this study was to investigate the risk of cancer in a large cohort of patients with acromegaly compared with matched controls. The comprehensive computerized database of the largest healthcare provider organization in Israel was searched for patients diagnosed with acromegaly in 2000–2021. All diagnoses were qualitatively validated. Patients were individually matched 1:5 with a control group for age, sex and socioeconomic status. Clinical and outcome data were collected from medical files. The final cohort consisted of 470 patients (54% male) with acromegaly and 2,330 control subjects. The mean age at diagnosis was 53 years, and the mean duration of follow-up after diagnosis was 10.4 years. The prevalence of solid malignancies was 21.3% in the acromegaly group and 14.8% in the control group (OR 1.6, 95% CI 1.2–2.0). Patients with acromegaly had a higher rate of thyroid cancer (2.8 vs 0.6%; OR 5.1, CI 2.3–11.0) and a tendency for a higher risk of colorectal cancer (3.6 vs 2.8%; OR 1.3, CI 0.7–2.2), prostate cancer (2.8 vs 1.7%; OR 1.6, CI 0.8–3.1) and renal cancer (1.5 vs 0.8%; OR 1.8, CI 0.8–4.4), but not hematological malignancies. They also had a higher mortality rate (21.3 vs 15.7%; OR 1.5, CI 1.1–1.9). In conclusion, the higher prevalence of malignant solid tumors in patients with acromegaly compared with control subjects suggests that periodic screening for early detection of solid cancers may be considered in this patient population.

24 August 2011
Verified
Reference Entry
Open access
PDF file
HDHadar Duskin‐Bitan
Hadar Duskin‐Bitan
SKShaye Kivity
Shaye Kivity
DODavid Olchovsky
David Olchovsky
GSGinette Schiby
Ginette Schiby
DEDavid Ezra
David Ezra
MMMeir Mouallem
Meir Mouallem

1 May 2020 in Maturitas
Verified
Journal Article
Closed access
HDHadar Duskin-Bitan
Hadar Duskin-Bitan
NNNina Nemirovsky
Nina Nemirovsky
ISIlana Slutzky-Shraga
Ilana Slutzky-Shraga
AGAlexander Gorshtein
Alexander Gorshtein
HMHiba Masri-Iraqi
Hiba Masri-Iraqi
GTGloria Tsvetov
Gloria Tsvetov